We Can Medicines Co., Ltd. (TPEX:6929)
Taiwan · Delayed Price · Currency is TWD 23.35
+0.95 (4.24%)
Aug 20, 2026, 11:13 AM CST
We Can Medicines Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,053 | 1,548 | 1,734 | 4,320 | 3,796 | - | |
Market Cap Growth | -26.64% | -10.72% | -59.87% | 13.80% | - | - |
Enterprise Value | 1,940 | 2,504 | 2,776 | 5,437 | 4,542 | - |
Last Close Price | 23.35 | 34.40 | 38.65 | 107.56 | 94.51 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | 291.83 | 37.94 | - |
PS Ratio | 0.33 | 0.48 | 0.53 | 1.38 | 1.15 | - |
PB Ratio | 1.04 | 1.48 | 1.55 | 5.29 | 4.80 | - |
P/TBV Ratio | 1.05 | 1.48 | 1.56 | 5.32 | 4.83 | - |
P/FCF Ratio | 3.72 | 7.57 | 8.81 | 91.36 | 16.94 | - |
P/OCF Ratio | 3.29 | 6.45 | 6.65 | 30.89 | 10.95 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.60 | 0.78 | 0.85 | 1.74 | 1.38 | - |
EV/EBITDA Ratio | 8.04 | - | 150.87 | 64.01 | 25.89 | - |
EV/EBIT Ratio | - | - | - | 227.09 | 38.76 | - |
EV/FCF Ratio | 6.85 | 12.24 | 14.11 | 114.98 | 20.27 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 1.10 | 1.14 | 1.11 | 1.61 | 1.34 | 1.30 |
Debt / EBITDA Ratio | 4.60 | 4.78 | 4.83 | 4.41 | 2.86 | 3.66 |
Debt / FCF Ratio | 3.93 | 5.86 | 6.31 | 27.84 | 4.72 | 7.58 |
Net Debt / Equity Ratio | 0.88 | 0.87 | 0.84 | 1.42 | 1.06 | 1.00 |
Net Debt / EBITDA Ratio | -88.57 | -1140.91 | 50.85 | 13.61 | 4.79 | 9.01 |
Net Debt / FCF Ratio | 3.13 | 4.46 | 4.76 | 24.45 | 3.75 | 5.85 |
Asset Turnover | 1.10 | 1.06 | 1.10 | 1.15 | 1.38 | 1.41 |
Inventory Turnover | 2.56 | 2.54 | 2.66 | 2.86 | 3.44 | 3.37 |
Quick Ratio | 0.51 | 0.55 | 0.57 | 0.41 | 0.43 | 0.46 |
Current Ratio | 1.50 | 1.53 | 1.59 | 1.24 | 1.28 | 1.28 |
Return on Equity (ROE) | -7.40% | -6.76% | -4.88% | 1.84% | 13.55% | 5.83% |
Return on Assets (ROA) | -1.62% | -1.40% | -1.05% | 0.55% | 3.06% | 0.95% |
Return on Invested Capital (ROIC) | -3.89% | -3.39% | -2.49% | 0.91% | 6.44% | 2.52% |
Return on Capital Employed (ROCE) | -4.00% | -3.40% | -2.30% | 1.30% | 7.00% | 2.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -7.41% | -4.73% | -2.72% | 0.34% | 2.64% | - |
FCF Yield | 26.88% | 13.21% | 11.35% | 1.09% | 5.90% | - |
Dividend Yield | - | - | - | 0.25% | - | - |
Buyback Yield / Dilution | -94.75% | -3.56% | -2.86% | -1.26% | -4.31% | -24.84% |
Total Shareholder Return | -94.75% | -3.56% | -2.86% | -1.01% | -4.31% | -24.84% |